Current Ratio
1.56x
Period-end balance · Through 30 Jun 2024
YoY relative change: +256%
Molecular Templates, Inc. financial metrics
Period Q2 2024 · Filed 14 Aug 2024
Key metrics snapshot
Debt-to-equity
4.55x
Period-end balance · Through 30 Jun 2024
YoY relative change: -128%
Financial Health
| Metric | Latest value | YoY relative change |
|---|---|---|
| Current Ratio |
1.56x
Period-end balance · 30 Jun 2024
|
+256% |
| Debt-to-equity |
4.55x
Period-end balance · 30 Jun 2024
|
-128% |
Share Metrics
| Metric | Latest value | YoY relative change |
|---|---|---|
| Entity Common Stock, Shares Outstanding |
6,583,880
Period-end balance · 09 Aug 2024
|
-92% |
| Common Stock, Shares, Outstanding |
6,583,880
Period-end balance · 30 Jun 2024
|
-88% |
| Common Stock, Value, Issued |
$7,000
Period-end balance · 30 Jun 2024
|
-88% |
| Weighted Average Number of Shares Outstanding, Basic |
6,557,295
Reported period · 30 Jun 2024
|
+75% |
| Weighted Average Number of Shares Outstanding, Diluted |
6,557,295
Reported period · 30 Jun 2024
|
+75% |
Supporting Metrics
These supporting metrics stay fully source-backed for deeper research. Scan the latest value and reported period first, then open a metric page when you need the full filing trail.
| Metric | Latest value | YoY relative change |
|---|---|---|
| Accounts Payable, Current |
$2,773,000
Period-end balance · 30 Jun 2024
|
-41% |
| Accrued Liabilities, Current |
$2,270,000
Period-end balance · 30 Jun 2024
|
-35% |
| Additional Paid in Capital |
$467,521,000
Period-end balance · 30 Jun 2024
|
+7.2% |
| Assets |
$26,697,000
Period-end balance · 30 Jun 2024
|
-25% |
| Assets, Current |
$12,016,000
Period-end balance · 30 Jun 2024
|
+1.6% |
| Cash and Cash Equivalents, at Carrying Value |
$9,657,000
Period-end balance · 30 Jun 2024
|
+95% |
| Common Stock, Par or Stated Value Per Share |
0
Period-end balance · 30 Jun 2024
|
0% |
| Common Stock, Shares Authorized |
150,000,000
Period-end balance · 30 Jun 2024
|
0% |
| Common Stock, Shares, Issued |
6,583,880
Period-end balance · 30 Jun 2024
|
-88% |
| Comprehensive Income (Loss), Net of Tax, Attributable to Parent |
$15,627,000
Trailing 12 months · 30 Jun 2024
|
+66% |
| Depreciation |
$4,800,000
Trailing 12 months · 30 Jun 2024
|
-40% |
| Earnings Per Share, Basic |
-1
Trailing 12 months · 30 Jun 2024
|
+97% |
| Earnings Per Share, Diluted |
-1
Trailing 12 months · 30 Jun 2024
|
+97% |
| Employee-related Liabilities, Current |
$43,000
Period-end balance · 30 Jun 2024
|
+153% |
| General and Administrative Expense |
$15,097,000
Trailing 12 months · 30 Jun 2024
|
-34% |
| Lessee, Operating Lease, Liability, to be Paid |
$13,073,000
Period-end balance · 30 Jun 2024
|
-20% |
| Lessee, Operating Lease, Liability, to be Paid, Year Four |
$2,148,000
Period-end balance · 30 Jun 2024
|
-19% |
| Lessee, Operating Lease, Liability, to be Paid, Year One |
$3,299,000
Period-end balance · 30 Jun 2024
|
-2.1% |
| Lessee, Operating Lease, Liability, to be Paid, Year Three |
$2,636,000
Period-end balance · 30 Jun 2024
|
+2.8% |
| Lessee, Operating Lease, Liability, to be Paid, Year Two |
$2,564,000
Period-end balance · 30 Jun 2024
|
-22% |
| Lessee, Operating Lease, Liability, Undiscounted Excess Amount |
$2,046,000
Period-end balance · 30 Jun 2024
|
-32% |
| Liabilities |
$19,586,000
Period-end balance · 30 Jun 2024
|
-56% |
| Liabilities and Equity |
$26,697,000
Period-end balance · 30 Jun 2024
|
-25% |
| Liabilities, Current |
$7,680,000
Period-end balance · 30 Jun 2024
|
-71% |
| Operating Income (Loss) |
$18,854,000
Trailing 12 months · 30 Jun 2024
|
+58% |
| Operating Lease, Liability |
$11,027,000
Period-end balance · 30 Jun 2024
|
-18% |
| Operating Lease, Liability, Current |
$2,637,000
Period-end balance · 30 Jun 2024
|
+12% |
| Operating Lease, Liability, Noncurrent |
$8,390,000
Period-end balance · 30 Jun 2024
|
-24% |
| Operating Lease, Right-of-Use Asset |
$8,124,000
Period-end balance · 30 Jun 2024
|
-20% |
| Operating Lease, Weighted Average Discount Rate, Percent |
0.08
Period-end balance · 30 Jun 2024
|
0% |
| Other Assets, Current |
$777,000
Period-end balance · 30 Jun 2024
|
-71% |
| Other Assets, Noncurrent |
$1,319,000
Period-end balance · 30 Jun 2024
|
-61% |
| Other Liabilities, Noncurrent |
$1,465,000
Period-end balance · 30 Jun 2024
|
+8.6% |
| Preferred Stock, Par or Stated Value Per Share |
0
Period-end balance · 30 Jun 2024
|
0% |
| Preferred Stock, Shares Authorized |
2,000,000
Period-end balance · 30 Jun 2024
|
0% |
| Preferred Stock, Shares Issued |
250
Period-end balance · 30 Jun 2024
|
0% |
| Preferred Stock, Shares Outstanding |
250
Period-end balance · 30 Jun 2024
|
0% |
| Property, Plant and Equipment, Gross |
$34,441,000
Period-end balance · 30 Jun 2024
|
-1.2% |
| Property, Plant and Equipment, Net |
$5,238,000
Period-end balance · 30 Jun 2024
|
-48% |
| Research and Development Expense |
$29,227,000
Trailing 12 months · 30 Jun 2024
|
-59% |
| Retained Earnings (Accumulated Deficit) |
$460,417,000
Period-end balance · 30 Jun 2024
|
-3.5% |
| Share-based Payment Arrangement, Expense |
$4,416,000
Trailing 12 months · 30 Jun 2024
|
-53% |
| Stockholders' Equity Attributable to Parent |
$7,111,000
Period-end balance · 30 Jun 2024
|
Comparisons, sources and research notes
Sources and sharing
Molecular Templates, Inc. Financial Facts
- Context
- Latest metrics period: Q2 2024
- Latest reported value
- Current Ratio 1.56x
Based on company facts extracted from SEC 10-Q/10-K XBRL filings where available. Open metric pages to inspect the reported history.
Tracking and update notes
Why revisit this company facts page
Company facts change as new 10-Q and 10-K filings update the latest reported period, headline values, and cross-company comparison context.
- Latest source-backed update
- Latest metrics period Q2 2024
- Why come back
- Use the next filing cycle to compare new facts against this baseline and then verify the detailed metric history.
- Current latest metrics period: Q2 2024.
- Most recent SEC facts end date on this page: 09 Aug 2024.
- Save this filer to return when the next filing-backed metric period changes the picture.
Freshness comes from the latest SEC company facts period available for this filer and the linked metric history pages.
Latest update
Latest update for Molecular Templates, Inc.
Latest financial period: Q2 2024. Reopen this facts page to verify the newest reported period against the prior baseline.
Update date
14 Aug 2024
Page type
Company facts
Latest period
Q2 2024
SEC-backed company facts were refreshed from filings filed on 14 Aug 2024.
Benchmark Context
How Current Ratio compares
Current Ratio is up about 256% versus the comparable prior period.
Compared with
Compared with Molecular Templates, Inc.'s recent history first. Same-industry peer context appears only when enough SEC-backed benchmark coverage exists.
Why this is notable
Current Ratio already has a self-history signal here, but same-industry benchmark context waits until the benchmark sample is strong enough.
- Latest comparable period on this page: Q2 2024.
- Peer context will appear when enough companies report a comparable value for this metric.
- Open the metric history first if you want to verify the exact period-to-period change.
Industry benchmark context uses SEC-reported values from the same methodology version. Latest periods may differ across companies.
Filing notes and source
Key facts
- Molecular Templates, Inc. financial facts use SEC filings; any third-party reference is labeled separately.
- Latest metrics period on this page: Q2 2024.
- Headline metric: Current Ratio 1.56x.
Change
- Current Ratio YoY relative change: +256%.
- Most recent SEC facts end date: 09 Aug 2024.
Research use
- This gives a beginner-friendly first read before you inspect detailed formulas and metric tables.
- Metric cards link to SEC history; a third-party reference may use a different or unverified reporting period.
Evidence
Based on latest 10-Q/10-K
View source filing
Based on company facts extracted from SEC 10-Q/10-K XBRL filings where available. Open company facts to inspect the reported metric history.
Latest financial snapshot (2024-08-09) highlights Current Ratio 1.56x and Debt-to-equity 4.55x.
Valuation Snapshot
SEC-only DCF estimate using a normalized free cash flow base, cash, debt, and reported share count when available.
No market comparison
No market comparison
Low confidence
Fair value per share
$60.50
Market price
n/a
PEG ratio
n/a
Enterprise value
$406.36M
Equity value
$396.7M
DCF fair value scenarios
Bear
$44.78
- Growth
- 1%
- Discount
- 11%
- Terminal
- 2%
Base
$60.50
- Growth
- 4%
- Discount
- 10%
- Terminal
- 2.5%
Bull
$85.25
- Growth
- 7%
- Discount
- 9%
- Terminal
- 3%
Base growth: DCF Growth Assumption.
Key valuation metrics
EV/Revenue
n/a
Market price market EV / SEC revenue
Market enterprise value is unavailable
EV/EBITDA
n/a
Market price market EV / SEC EBITDA
Market enterprise value is unavailable
P/E
n/a
Market price market price / SEC EPS
Market cap is unavailable
P/S
n/a
Market price market cap / SEC revenue
Market cap is unavailable
P/B
n/a
Market price market cap / SEC equity
Market cap is unavailable
PEG
n/a
P/E / DCF Growth Assumption
P/e or positive growth is unavailable
Core assumptions
- Projection
- 5 years
- FCF growth
- 4%
- Discount rate
- 10%
- Terminal growth
- 2.5%
SEC fact inputs
- DCF base FCF
- $27.9M
- Trailing SEC FCF
- Reported FCF
- $27.9M
- Net income
- $8.12M
- EBITDA
- $13.02M
- Cash
- $9.66M
- Debt
- n/a
- Equity
- $7.11M
- Shares
- 6,557,295
Data confidence notes
- Dcf base free cash flow: dcf base starts from trailing sec free cash flow
- Dcf base free cash flow: trailing free cash flow is not positive
- Dcf confidence is low for this sec-only free cash flow estimate
- Ticker missing for issuer
- Debt missing: equity value treats debt as 0
- Base free cash flow is negative; dcf output is mechanically computed but high risk
- Peg unavailable: market price is missing
Financial Quality Score
Transparent 0-100 scoring model based on profitability, financial health, and growth factors.
54.5/100
Caution Confidence low
Financial Health
- Current Ratio
- 1.56x
- Debt to Equity
- 4.55x
Strengths
Current Ratio
Watchpoints
Debt-to-equity
Calculation methodology and other links
How we score
This score is transparent and deterministic. We weight profitability, financial health, and growth metrics, then renormalize weights when SEC data is missing.
| Metric | Weight | V1 threshold |
|---|---|---|
| ROIC | 20 | 5% to 20% |
| ROE | 15 | 8% to 25% |
| ROA | 10 | 2% to 10% |
| Operating Margin | 5 | 5% to 25% |
| Current Ratio | 12 | 1.0x to 2.0x |
| Quick Ratio | 8 | 0.8x to 1.5x |
| Debt to Equity | 10 | 0.3x to 2.0x (lower is better) |
| Revenue YoY | 10 | -10% to +20% |
| Net Income YoY | 10 | -10% to +20% |
How Calculated (standard_v1)
Metrics are computed with a market-consensus convention designed for cross-portal comparability.
- Operating Income / Revenues using matching TTM or quarter periods; basis shown per metric
- Current Assets / Current Liabilities (latest instant quarter)
- (Current Assets - Inventory) / Current Liabilities; fallback: (Cash+Short-Term Investments + Accounts Receivable) / Current Liabilities
- Total Debt / Stockholders Equity (latest instant quarter; shared unit; freshest series)
- TTM Net Income / Average Equity (current quarter + same quarter previous year) / 2
- TTM Net Income / Average Assets (current quarter + same quarter previous year) / 2
- TTM NOPAT / Average Invested Capital, where NOPAT=Operating Income*(1-tax rate), Invested Capital=Equity+Total Debt-Cash & ST Investments
- Revenues YoY using available TTM or quarter comparison; basis shown per metric
- Net Income YoY using available TTM or quarter comparison; basis shown per metric
CIK / security context first